胆固醇胺在血液透析中:一种新的方法来管理高酸血症
Ahmed Essam Abd El Hady Ali Ghanem1, Radwa Maher El Borolossy1, Tamer Wahid El Said2
1Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo 11571, Egypt.
概括
胆固醇胺有效降低血液透析患者的血清酸盐水平,改善心血管健康. 这项研究显示,随着胆固醇胺治疗,和-x-产品显著减少.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
背景情况:
- 过血是末期病 (ESRD) 患者接受血液透析的严重并发症,与心血管化和骨疾病有关.
- 胆汁酸分离剂,如胆固醇胺,在肠道中结合酸,减少吸收,并可能控制高酸血症和高胆固醇血症.
研究的目的:
- 评估口服胆固醇胺在降低成人血液透析患者血清酸盐水平方面的疗效.
- 评估胆固醇胺对血清酸产品和脂质谱的影响.
主要方法:
- 一项前性,随机,双盲,安慰剂控制的研究,涉及76名成年血液透析患者.
- 患者被分配给接受口服胆固醇胺或安慰剂,为期2个月.
- 血清酸盐,酸产品,甘油三和LDL胆固醇水平被监测.
主要成果:
- 与安慰剂相比,胆固醇胺显著降低了血清水平 (4.6 mg/dl与6.6 mg/dl相比; p < 0.001).
- 在胆固醇胺组中观察到-产品的显著下降 (40 mg2/dl2对比59.8 mg2/dl2;p < 0.001).
- 胆固醇胺还导致血清甘油三和LDL胆固醇水平从基线显著降低.
结论:
- 口服胆固醇胺有效降低血液透析患者的血清酸盐水平.
- 胆固醇胺改善脂质配置文件,并表现出良好的安全性,但副作用轻微.
- 这种药物代表了管理ESRD患者的高酸血症和相关并发症的宝贵选择.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
522
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
522
01:29Chronic Pancreatitis II: Collaborative Care
60
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
60
01:26Peptic Ulcer Disease IV: Management
60
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
60
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
131
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131
01:26Anticholinesterase Agents: Poisoning and Treatment
776
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
776
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
146
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
146